| id |
crelifesciences:10.7554/elife.14847.011
|
| record_format |
openpolar
|
| spelling |
crelifesciences:10.7554/elife.14847.011 2023-07-23T04:19:01+02:00 Figure 7. NOTCH regulates SNAI1 degradation through inhibition of GSK-3β activity. (A) Confocal stacks of somites, 6 hr after electroporation of RFP (in red) and SNAI1-GFP (fusion of SNAI1 and GFP, in green) alone or together with NICD. (B) Confocal stacks of somites, 6 hr after electroporation of GSK-3β biosensor (in green) and RFP (in red) alone (left), or together with NICD (right). (C) Confocal stacks of a somite 6 hr after co-electroporation of the GSK-3β biosensor (green) and the NOTCH reporter (red) and immunostained for MYF5 (blue). (D,E) Bar charts showing the% of GSK-3β biosensor-positive cells that activate NOTCH signaling (86.9%, D) and that are MYF5-positive (88.2%, E). (F) Confocal stacks of a somite 6 hr after co-electroporation of a SNAI fused to RFP (in red) and the GSK-3β biosensor (in green). In blue the electroporated cells, identified by H2B-BFP. (G) Bar charts showing 89.4% of DML electroporated cells are GSK-3β biosensor and SNAI1-positive. (H) Confocal stacks of somites and adjacent neural tube electroporated as described in Figure 4H, only in the DML with the GSK-3β biosensor (in green) and H2B-BFP (in blue, left panels) or double-electroporated in the DML with the GSK-3β biosensor (in green) and H2B BFP (in blue) and in the neural tube with DLL1 under the control of a neural crest-specific promoter (right panels). (I) Bar charts showing the% of GSK-3β biosensor-positive cells in the control (26.4%, in white) or with DLL1 expressed in the neural crest (64.6%, in black). (J) Confocal stacks of somites 17 hr after electroporation of GFP as control or DN-GSK-3β and immunostained for MYF5 (red). (K) Bar charts showing the% of electroporated cells that have entered the primary myotome in the control (45.8%, in white) of with the DN-GSK-3β (61.2%, in black). (L) Bar charts showing the% of electroporated cells that are MYF5-positive in the control (23.1%, in white) of with the DN-GSK-3β (57.2%, in black). In each panel are indicated the antigens that were detected by immunostaining, with the exception of native BFP blue fluorescence. Abbreviation: EP: electroporation; NT: neural tube. Scale bars: 50 μm. 2016-06-23T14:51:06Z http://dx.doi.org/10.7554/elife.14847.011 unknown eLife Sciences Publications, Ltd component 2016 crelifesciences https://doi.org/10.7554/elife.14847.011 2023-07-05T08:36:07Z Other/Unknown Material DML eLife (E-Journal - via Crossref)
|
| institution |
Open Polar
|
| collection |
eLife (E-Journal - via Crossref)
|
| op_collection_id |
crelifesciences
|
| language |
unknown
|
| format |
Other/Unknown Material
|
| title |
Figure 7. NOTCH regulates SNAI1 degradation through inhibition of GSK-3β activity.
|
| spellingShingle |
Figure 7. NOTCH regulates SNAI1 degradation through inhibition of GSK-3β activity.
|
| title_short |
Figure 7. NOTCH regulates SNAI1 degradation through inhibition of GSK-3β activity.
|
| title_full |
Figure 7. NOTCH regulates SNAI1 degradation through inhibition of GSK-3β activity.
|
| title_fullStr |
Figure 7. NOTCH regulates SNAI1 degradation through inhibition of GSK-3β activity.
|
| title_full_unstemmed |
Figure 7. NOTCH regulates SNAI1 degradation through inhibition of GSK-3β activity.
|
| title_sort |
figure 7. notch regulates snai1 degradation through inhibition of gsk-3β activity.
|
| publisher |
eLife Sciences Publications, Ltd
|
| publishDate |
2016
|
| url |
http://dx.doi.org/10.7554/elife.14847.011
|
| genre |
DML
|
| genre_facet |
DML
|
| op_doi |
https://doi.org/10.7554/elife.14847.011
|
| _version_ |
1772181772605325312
|